Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Zydus Lifesciences plans Phase III Desidustat trial sickle cell ICMR — Jul 23, 2026Zydus Lifesciences has received regulatory approval to initiate a 203-day Phase III trial of Desidustat for sickle cell disease in collaboration with ICMR, enrolling 164 patients to assess efficacy and safety of the oral tablet. The move follows successful Phase II results and US FDA Orphan Drug Designation, underscoring a public-private effort to address India's substantial SCD burden.